Anything but IMO. I like it as well as SRPT now, maybe more from risk/reward standpoint. Also a couple of other relatively undervalued ones in RNA space, TKMR, ARWR - compared to ALNY, ISIS. I think they'll do really well in orphan disease space.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.